 |
|
|
|
 |
|
|
|
|
|
|
Departments
|
Pediatric Oncology
Surgery
|
|
Hospital Title
|
Pediatric Oncology Attending
|
|
Academic Title
|
Instructor in Pediatrics
|
|
Phone
|
617-919-2396
|
|
Fax
|
617-730-0002
|
|
Email
|
Giannoula Klement
|
|
Location
|
300 Longwood Avenue
Boston MA 02118
|
 |
 |
|
|
|
|
|
|
|
Giannoula Klement is a pediatric hematologist/oncologist with a basic research focus in tumor angiogenesis. She joined Vascular Biology Program in the Department of Surgery at Children's Hospital in July 2003 to work on a collaboration between the Pediatric Oncology Program at Dana-Farber Cancer Institute and the Vascular Anomalies Center at Children's Hospital. The goal of the collaboration was development of novel medical therapies for children with life-threatening and untreatable vascular anomalies and brain tumors.
Her expertise in antiangiogenic therapy makes her particularly well suited for this position. She has made a significant contribution to the field of angiogenesis with research focusing on the use of established chemotherapeutic agents for antiangiogenic therapy (J Clin Invest 2000; 105: R15-R24, Science 2000; 288: 245, Nat Med 2000; 6: 500-502). Her work has led to several clinical trials combining antiangiogenic chemotherapy with tyrosine kinase inhibitors in cancer treatment. She is presently working on developing a similarly comprehensive clinical oncology program for the Vascular Anomalies Center here at Children's Hospital.
Dr. Klement's present basic science focus is the study of platelet proteome. She has demonstrated that the profile of positive and negative angiogenesis regulators in platelets can be used to identify microscopic human cancers in immunodeficient mice (Blood 2004; 104:11,839a). Some of these angiogenesis related proteins in platelets can be used as markers of early tumor growth (Blood 2006; 108:11, 1476a). She is presently exploring the mechanisms in which platelets sense the need for angiogenic growth factors, selectively uptake various angiogenic regulators and transport these proteins to the tumors or wound site. Early work from her laboratory suggests that angiogenesis related proteins are selectively released from platelets at sites of an activated endothelium (such as tumor or a wound) by the activation of protease activated receptors 1 and 4 (Blood 2006,108:11,393a).
Dr. Klement is also closely involved in developing novel therapeutic approaches for patients with untreatable vascular anomalies. In particular, she has developed a clinically applicable regimen of low dose chemotherapy based on her pre-clinical evidence with cytoskeletal inhibitors for the treatment of tumors. She has developed novel medical therapies using available antiangiogenic agents such as thalidomide for vascular malformations, which could previously be treated only by surgery or endovascular radiological intervention. Based on early evidence with these pilot cases, she is developing protocol for a clinical trial.
|
|
|
|
|
|
Dr. Klement received an MD from McMaster University, Hamilton, Canada, and completed post-graduate training at the Hospital for Sick Children, University of Toronto.
|
|
|
|
|
- Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, Kerbel RS. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest. 2000;105(8):R15-24.
- Klement G, Huang P, Mayer B, Green SK, Man S, Bohlen P, Hicklin D, Kerbel RS. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin Cancer Res. 2002;8(1):221-32.
- Rak J, Klement G. Impact of oncogenes and tumor suppressor genes on deregulation of hemostasis and angiogenesis in cancer. Cancer Metastasis Rev. 2000;19(1-2):93-6.
|
|
|
|
|
|
|
|
|
|
|
